Search This Blog

Sunday, August 30, 2020

Revamped Dow Set to Widen Gap With S&P 500

Even before Apple Inc. unveiled plans for a stock split, the Dow Jones Industrial Average struggled this year to keep up with its broader counterpart, the S&P 500 index.

The addition of three new components on Monday — when Apple starts trading on a split-adjusted basis — likely won’t help matters.

That is because the revamped Dow industrials put less emphasis on technology stocks, the engine behind the stock market’s rebound from the lows of March. Starting Monday, tech will constitute less than a quarter of the Dow’s weight versus nearly 28% for the S&P 500. The broader index includes Amazon.com Inc., Facebook Inc. and Google parent Alphabet Inc. — none of which are in the Dow.

With millions of people still homebound, technology stocks have been clear winners during the coronavirus crisis. People are working from home, streaming movies and using social media to connect with friends and family, hastening the adoption of tech in their everyday lives. Those changes in behavior have made big tech stocks among the few reliable bets during a crisis that has upended most other businesses.

“With the economy we have now because of Covid-19 and the difference between whether companies are open or not, over the short term we could see a significant variance continuing,” said Howard Silverblatt, a senior index analyst at S&P Dow Jones Indices.

The S&P 500 is outperforming the Dow industrials by roughly 8 percentage points in 2020 — the widest gap since 1932, according to Dow Jones Market Data. Short-term rifts between the two benchmarks aren’t uncommon, said Mr. Silverblatt, and the Dow and the S&P 500 tend to track each other more closely over longer periods. But this year has been markedly different due to how the pandemic has deepened a split within the market along familiar lines: growth versus value.

Many tech and communications companies in the S&P 500 are growth stocks, or those that promise to deliver faster-than-average profit growth in the future. More staid businesses, such as industrial and financial companies, are often in the value bucket and typically trade at low valuation multiples.

Growth stocks in the S&P 500 have soared 25% this year versus an 11% decline for value shares. The outperformance of growth stocks has driven the market-cap-weighted S&P 500 up 57% from its March 23 trough and 8.6% for the year.

The Dow tilts more toward value by having a bigger representation of industrial, financial and health-care stocks relative to the S&P 500. Its price-weighted structure doesn’t usually help matters, since stocks with the highest share price have the most influence.

The run-up in Apple’s share price this year has benefited both indexes and kept the gap from widening even further. Shares of Apple have traded higher than the 29 other Dow stocks for much of the year, contributing more than 1,400 points to the index. And Apple’s 70% gain since the end of December has pushed its market cap above a record $2 trillion.

Before Apple’s 4-for-1 stock split, tech stocks represented 28% of the Dow, on par with the S&P 500. But some of its other most powerful constituents based on share price — Goldman Sachs Group Inc., Boeing Co. and Caterpillar Inc. — are down in 2020. And the Dow’s most influential stock following the Apple split, UnitedHealth Group Inc., is up just 6.9% this year.

Apple’s split would have put a serious dent in the tech sector’s influence in the Dow. The committee that manages the Dow, which includes editors of The Wall Street Journal, which is published by Dow Jones & Co., a part of News Corp, sought to rectify the imbalance by replacing Exxon Mobil Corp. with Salesforce.com Inc., along with two other component swaps. But those changes nudged tech’s weighting up only to 24%.

“I don’t think it means as much as it did in the 1930s,” said Nate Fischer, chief investment strategist at Strategic Wealth Partners.

The disconnect, for however long it might last, isn’t a major concern, said Mr. Silverblatt of S&P Dow Jones Indices. After all, the Dow isn’t meant to imitate the S&P 500 or any other index. Instead, the Dow’s construction is intended to emulate the top of the U.S. stock market, he said.

Take the inclusion of Salesforce. Its addition not only nudged tech’s weighting in the Dow higher, but it also diversified the sector’s representation by adding a pure-play cloud company. When it came time to decide what Salesforce would replace, an energy stock was the obvious choice, Mr. Silverblatt said.

Similar thinking likely played out with the Dow’s other changes. Pfizer Inc. has the lowest share price of the 30 stocks in the index, diminishing the health-care sector’s influence. Its replacement, Amgen Inc., boosts the sector’s heft. Meanwhile, Raytheon Technologies Corp.’s business following the merger with UnitedTechnologies Corp. overlapped with aerospace and defense giant Boeing Co. The substitution of Honeywell International Inc. diversifies the Dow’s industrial stocks.

There are limitations to the Dow. Investors have long questioned why Amazon and Alphabet aren’t included when they represent the 21st century economy. Their hefty share prices would wreak havoc on the index by drastically boosting the weightings of their corresponding sectors. That underscores why $31.5 billion in assets are linked to the Dow through index funds versus more than $11 trillion for the S&P 500.

That hasn’t fazed some investors who have hitched their portfolios to the Dow. Tim Courtney, chief investment officer of Exencial Wealth Advisors, said several clients have sought to follow the Dow by buying shares of a $23 billion exchange-traded fund that tracks the index, the SPDR Dow Jones Industrial Average ETF Trust.

“Some investors think they’re getting better exposure to the broader economy, and you might want to do that if you feel like market weightings in the other two indexes have gone too far,” said Mr. Courtney. “They’re more concerned about valuations so they go to an area not so focused on growth.”


Demand for Online Doctors Creates $39 Billion Titan in Japan

Two decades ago, Itaru Tanimura ended a 12-year run at McKinsey & Co. to lead M3 Inc., an online provider of medical information and services backed by entertainment giant Sony Corp.

What followed was a flurry of acquisitions that turned the Tokyo-based company into a $39 billion global behemoth. M3 now has about 40 subsidiaries and affiliates, including MDLinx Inc. in the U.S. and Britain’s Doctors.net.uk Ltd.

M3 helps pharmaceutical companies, doctors and their patients access information online over its platforms, removing the need for in-person visits — something that proved important in the time of Covid-19. Its shares have almost doubled this year, surging the most of any company in the Nikkei 225 Stock Average and taking the fortune of Tanimura to $1.2 billion, according to the Bloomberg Billionaires Index.

“Online doctor capabilities are in the spotlight with Covid, as people are staying home,” Jefferies Japan Ltd. analyst Hiroko Sato said in an interview. “It’s really a theme stock.”

Inquiries Skyrocket

A rush by smaller pharma companies to digitalize marketing materials after the coronavirus outbreak helped boost sales, with inquiries skyrocketing. M3’s operating profit climbed 26% in the quarter ended in June, beating the highest analyst estimate.

The company’s name stands for “the three Ms of Medicine, Media and Metamorphosis,” and its goal is to change medicine by “making full use of the power of the Internet,” according to its website.

Its acquisition spree started in 2002, when M3 bought the Japanese unit of U.S. medical portal site WebMD. MDLinx was acquired in 2006 and Doctors.net.uk in 2011. M3, which gets about three-quarters of its revenue from Japan, also has units in China, India and France. One of its U.S. subsidiaries was selected to take part in Moderna Inc.’s Covid-19 vaccine study.

Tanimura, 55, is president and holds a 2.9% stake in M3. Sony owns about a third of the company. M3 declined to comment for this story, while Sony didn’t respond to phone calls and an email seeking comment.

Tech Wealth

The pandemic has produced vast wealth gains among both tech and pharma titans. Amazon.com Inc.’s Jeff Bezos has amassed more than anyone else, with his fortune hitting $200 billion, while Tencent Holdings Ltd.’s Pony Ma and Jiang Rensheng, the chairman of vaccine maker Chongqing Zhifei Biological Products Co., have added more than $11 billion each.

While M3 said in its earnings report that Covid-19 disrupted some of its business, it always has Sony to lean on. The entertainment giant unveiled a $100 million relief fund to help tackle the outbreak in April and funneled some of that cash toward M3.

“Sony and M3 will be able to bring unprecedented ideas to the medical community,” Tanimura said at the time. “Our first priority will be the rapid development of contributive measures to the fight against Covid-19.”


Vaccine diplomacy: Mexico courts allies across ideological spectrum

Mexico is pressing ahead with an effort to forge COVID-19 vaccine alliances across a wide ideological spectrum of countries from France to Cuba as a World Health Organization (WHO) vaccine initiative will fall short of its needs.

Mexico joined in early June the WHO’s global COVAX plan, which aims to deliver at least 2 billion doses of approved vaccines by the end of next year and ensure “equitable access.”

But Martha Delgado, a Mexican deputy foreign minister whom President Andres Manuel Lopez Obrador put in charge of Mexico’s international response, told Reuters its share of that program was unlikely to be enough to provide the roughly 200 million vaccine doses Mexicans will need.

“We can’t depend on it,” said Delgado. “COVAX promises to help with 20% of the population – we need a bigger quantity of vaccines and so do other countries as well.”

Delgado’s boss, Foreign Minister Marcelo Ebrard, has been reporting in regularly to Lopez Obrador about the latest developments in the effort to secure a vaccine – or vaccines – that will curtail Mexico’s novel coronavirus outbreak, she said, an effort embracing all major superpowers and their allies.

Left-wing populist Lopez Obrador has raised eyebrows in some quarters by forging a close alliance with U.S. President Donald Trump. But Ebrard has also assiduously courted China, which has provided Mexico with such equipment as ventilators and masks. And Lopez Obrador has offered to personally test the Russian vaccine despite misgivings among some scientists.

The foreign ministry underscored, in an emailed statement, that “vaccine nationalism” should be avoided because “no one will be safe until everyone is safe, and for that reason, negotiation, diplomacy and multilateralism play a crucial role.”

Delgado said her daily schedule is packed talking to healthcare sector representatives, ambassadors, foreign ministries, laboratories and doctors.

“We have chosen to do this via our diplomatic channels, get access to information and pharmaceutical companies through cooperation with other countries,” Delgado said.

“Why go this route? Firstly, the countries themselves are going to certify their vaccines, their safety, not the pharmaceutical companies.

“And secondly because Mexico has diplomatic prestige,” said Delgado, pointing to a United Nations resolution it successfully sponsored to guarantee universal access to medicines, vaccines and medical equipment to face COVID-19.

The strategy seems to be working.

Mexico will take part in clinical trials of the Italian GRAd-COV2 vaccine and has agreed for 2,000 volunteers to participate in trials of Russia’s “Sputnik V” vaccine.

It has also struck a deal to produce pharmaceutical firm AstraZeneca Plc’s (AZN.L) vaccine. In addition, it is looking to participate in phase 3 trials with French drugmaker Sanofi (SASY.PA), Johnson & Johnson’s (JNJ.N) Janssen unit and Chinese companies CanSino Biologics Inc (6185.HK) and Walvax Biotechnology Co Ltd (300142.SZ), all of which have agreed to guarantee access to their vaccines if successful.

It plans to talk to Cuba about its so-called Soberana 01, or Sovereign 01, vaccine and the German government about biotechnology firm CureVac CVAC.O, which is researching how to use messenger RNA to treat a series of diseases, including the coronavirus.

Mexico’s vaccine diplomacy may have even helped nudge Russia to perform a late-stage trial of its vaccine, which will involve more than 40,000 people and be overseen by a foreign research body.

“Sputnik V,” named in homage to the world’s first satellite launched by the Soviet Union, has been hailed as safe and effective by Russian authorities and scientists following two months of small-scale human trials.

But Western experts have warned against its use until all internationally approved testing and regulatory steps have been taken.

The Russians wanted to donate vaccines for the Mexicans to test as a finished product, but Mexico first wanted more information on the phase 1 and 2 trials, said Delgado.

Now Russia has agreed to conduct Phase 3 trials on the vaccine, with some of them happening in Mexico itself, she said.


Biotech week ahead, Aug. 31

Biotech stocks went about a consolidation move in the week ended Aug. 28 amid thin news flow. Barring updates on coronavirus vaccine/treatment candidates, there was very little for the sector to react to.

The second half of the week saw the Liver Congress kicking in, with a slew of updates coming from companies working on liver-related ailments.

Here’re the key catalysts for the unfolding week:

Conferences

European Society of Cardiology, ESC, Congress 2020: Aug. 29 – Sept. 1
46th Annual Meeting of the European Society for Blood and Marrow Transplantation, or EBMT: Aug. 29 – Sept. 1
eCongress of European Congress of Endocrinology, or ECE: Sept. 5-9

PDUFA Dates

FDA is scheduled to rule on Bristol-Myers Squibb Co’s BMY 0.24% NDA seeking approval for CC-486, its Investigational oral hypomethylating agent, for the maintenance treatment of adult patients with acute myeloid leukemia. (Thursday)

Adcom Meetings

FDA’s Pulmonary-Allergy Drugs Advisory Committee is scheduled to discuss GlaxoSmithKline plc’s GSK 0.39% sNDA for Trelegy Ellipta, a fixed-dose combination of fluticasone furoate, umeclidinium, and vilanterol inhalation powder oral inhalation, for use in patients with chronic obstructive pulmonary disease.

Clinical Readouts

Standalone releases

Cue Biopharma Inc CUE 0.45% is scheduled to provide an update on its ongoing Phase 1 clinical trial of CUE-101 for the treatment of HPV16-driven recurrent/metastatic head and neck squamous cell carcinoma. (Monday at 4:30 pm ET)

Acasti Pharma Inc (NASDAQ: ACST is due to release topline results from the Phase 3 TRILOGY 2 study on or about August 31. The study is evaluating CaPre, a highly purified omega-3 phospholipid concentrate derived from krill oil that is being developed to treat severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis.

EBMT Presentations

Incyte Corporation INCY 0.42%: oral presentation of already-released Phase 3 REACH2 data that demonstrated Jakafi improved outcomes across a range of efficacy measures in patients with steroid-refractory acute graft-versus-host disease

Orchard Therapeutics PLC – ADR ORTX 18.57%: New interim data from OTL-203, an investigational gene therapy for the treatment of mucopolysaccharidosis type I (Monday)

ESC Presentations

Arrowhead Pharmaceuticals Inc ARWR 0.31%: RNA interference targeting apolipoprotein C-3 with ARO-APOC3 in Familial chylomicronemia syndrome / Hypertriglyceridemia (Monday)

AstraZeneca plc AZN 0.74%: detailed results from the Phase 3 DAPA-CKD trial of Farxiga in chronic kidney disease (Monday)

Novartis AG NVS 0.44%: Entresto late-breaking data of Phase 3 Parallax-HF trial in chronic heart failure patients with preserved ejection fraction, with endpoints on biomarkers, symptoms and functional measures (Monday)

ECE Presentations

AEterna Zentaris Inc. AEZS 1.06%: results of the Phase 1 pediatric study of macimorelin in suspected growth hormone deficiency

Earnings

Catalent Inc CTLT 0.02% (Monday, before the market open)
I-Mab ADR IMAB 0.77% (Monday, before the market open)
Avid Bioservices Inc CDMO 0.12% (Tuesday, after the close)
Misonix Inc MSON 1.62% (Thursday, after the close)
Cooper Companies Inc COO 1.11% (Thursday, after the close)

IPO Quiet Period Expiry

Acutus Medical Inc AFIB 3.2%
Checkmate Pharmaceuticals Inc CMPI 1.42%
Freeline Therapeutics Holdings PLC FRLN 2.06%

Other Key Events

Castle Biosciences Inc CSTL 0.52% is scheduled to host a conference call Sept. 2 at 4:30 p.m. ET, to highlight the planned commercial launch of DecisionDx-SCC, its prognostic gene expression profile test for patients diagnosed with high-risk cutaneous squamous cell carcinoma.

Federal Circuit appellate hearing related to a patent on Amarin Corporation plc’s AMRN 3.66% Vascepa is scheduled for Wednesday.